Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (12344)	11/27/1999 12:32:00 AM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Xoma.........ain't nothing but a hound dog? >>>>New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis. Beringer PM Department of Clinical Pharmacy, USC School of Pharmacy, Los Angeles 90033, USA. Chronic pulmonary infections are a significant cause of morbidity and mortality in patients with cystic fibrosis. The traditional approach to managing patients with cystic fibrosis is to treat acute exacerbations with antimicrobial, airway clearance, and nutritional therapies. Advances in the understanding of the pharmacodynamics of antibiotics have led to the development of new dosing strategies to maximize the antibiotics' activity. Recent data on the use of aerosolized tobramycin as chronic maintenance therapy have demonstrated that it improves pulmonary function significantly and reduces hospitalization days. New insights into the pathogenesis of pulmonary disease have led to the development of novel therapies, including salt-insensitive antimicrobial peptides and rBPI21, as adjunctive therapy to increase the sensitivity of current antibiotics. In addition, macrolide antibiotics are being investigated for their anti-inflammatory effects as chronic maintenance therapy. Until effective therapies are available to correct the basic genetic defect that causes cystic fibrosis, antibacterial and anti-inflammatory agents will continue to be the mainstay of treatment. <<<<<<<<<<<,